Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma

被引：9
作者：
Martinez-Trufero, Javier [1 ]
Alfaro, Jorge [2 ]
Felipo, Francesc [2 ]
Alvarez, Maria [1 ]
Madani, Julia [1 ]
Cebollero, Ana [1 ]
机构：
[1] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza 50009, Spain
[2] Hosp Univ Miguel Servet, Dept Pathol, Zaragoza 50009, Spain
来源：
ANTI-CANCER DRUGS | 2010年 / 21卷 / 08期
关键词：
hemangiopericytoma; rare tumor; solitary fibrous tumor; trabectedin; SOFT-TISSUE SARCOMA; CENTRAL-NERVOUS-SYSTEM; MALIGNANT HEMANGIOPERICYTOMA; PHASE-II; FIBROUS TUMOR; ECTEINASCIDIN-743; CHEMOTHERAPY; RADIOTHERAPY; EXPERIENCE; SUNITINIB;
D O I：
10.1097/CAD.0b013e32833d19f0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Meningeal hemangiopericytoma is an uncommon and aggressive malignancy that, in contrast to meningiomas, shows a high propensity for local recurrence and the development of late extraneural metastases. The results of chemotherapy in advanced hemangiopericytoma have been disappointing, and they have been particularly poor in cases located in the meninges. We report a case of a heavily pretreated metastatic meningeal hemangiopericytoma in which fourth-line chemotherapy with trabectedin, a marine-derived antineoplastic agent effective in treating advanced soft tissue sarcomas, resulted in clinical benefit. Anti-Cancer Drugs 21: 795-798 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码：795 / 798
页数：4
相关论文
共 50 条
  • [41] Trabectedin in Advanced High-Grade Uterine Leiomyosarcoma: A Case Report Illustrating the Value of (18)FDG-PET-CT in Assessing Treatment Response
    Payne, M. J.
    Macpherson, R. E.
    Bradley, K. M.
    Hassan, A. B.
    CASE REPORTS IN ONCOLOGY, 2014, 7 (01): : 132 - 138
  • [42] Initial Response to First Line Treatment is the Best Predictor of the Patient Survival in Advanced NSCLC
    Turhal, N.
    Orscelik, S.
    Taktakoglu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1001 - S1001
  • [43] Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
    Toulmonde, Maud
    Brahmi, Mehdi
    Giraud, Antoine
    Chakiba, Camille
    Bessede, Alban
    Kind, Michele
    Toulza, Emilie
    Pulido, Marina
    Albert, Sabrina
    Guegan, Jean-Philippe
    Cousin, Sophie
    Mathoulin-Pelissier, Simone
    Perret, Raul
    Croce, Sabrina
    Blay, Jean-Yves
    Ray-Coquard, Isabelle
    Floquet, Anne
    Italiano, Antoine
    CLINICAL CANCER RESEARCH, 2022, 28 (09) : 1765 - 1772
  • [44] Manifestation of leukoencephalopathy in a patient with advanced non-small cell lung cancer following treatment with gefitinib
    Huang Yi-sheng
    Huang Biao
    Wu Yi-long
    CHINESE MEDICAL JOURNAL, 2011, 124 (22) : 3834 - 3837
  • [45] Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
    Cesne, A. L.
    Judson, I.
    Maki, R.
    Grosso, F.
    Schuetze, S.
    Mehren, M. V.
    Chawla, S. P.
    Demetri, G. D.
    Nieto, A.
    Tanovic, A.
    Blay, J-Y
    BRITISH JOURNAL OF CANCER, 2013, 109 (07) : 1717 - 1724
  • [46] Trabectedin as second-line treatment in advanced soft tissue sarcoma: quality of life and safety outcomes
    Grignani, Giovanni
    Le Cesne, Axel
    Martin-Broto, Javier
    FUTURE ONCOLOGY, 2022, 18 (30S) : 13 - 22
  • [47] Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
    Paz-Ares, Luis
    Lopez-Pousa, Antonio
    Poveda, Andres
    Balana, Carmen
    Ciruelos, Eva
    Bellmunt, Joaquim
    Garcia del Muro, Javier
    Provencio, Mariano
    Casado, Antonio
    Rivera-Herrero, Fernando
    Izquierdo, Miguel Angel
    Nieto, Antonio
    Tanovic, Adnan
    Cortes-Funes, Hernan
    Maria Buesa, Jose
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 729 - 740
  • [48] Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13)
    Kasper, Bernd
    Pink, Daniel
    Rothermundt, Christian
    Richter, Stephan
    Augustin, Marinela
    Kollar, Attila
    Kunitz, Annegret
    Eisterer, Wolfgang
    Gaidzik, Verena
    Brodowicz, Thomas
    Egerer, Gerlinde
    Reichardt, Peter
    Hohenberger, Peter
    Schuler, Markus K.
    CANCERS, 2024, 16 (03)
  • [49] Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma
    Yalcin, Suayib
    Lacin, Sahin
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 7779 - 7785
  • [50] Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used
    Ogata, Dai
    Namikawa, Kenjiro
    Otsuka, Masaki
    Asai, Jun
    Kato, Hisoshi
    Yasuda, Masahito
    Maekawa, Takeo
    Fujimura, Taku
    Kato, Junji
    Takenouchi, Tatsuya
    Nagase, Kotaro
    Kawaguchi, Masakazu
    Kaji, Tatsuya
    Kuwatsuka, Yutaka
    Shibayama, Yoshitsugu
    Takai, Toshihiro
    Okumura, Mao
    Kambayashi, Yumi
    Yoshikawa, Syusuke
    Yamazaki, Naoya
    Tsuchida, Tetsuya
    EUROPEAN JOURNAL OF CANCER, 2020, 127 : 108 - 117
12345